Literature DB >> 28391773

KIF13B-NRG1 Gene Fusion and KRAS Amplification in a Case of Natural Progression of Lung Cancer.

Daniel Xia1,2, Long Phi Le1, Anthony John Iafrate1, Jochen Lennerz1.   

Abstract

An 85-year-old woman with a history of several primary lung cancers presented with liver metastases. The primary lung cancers were all managed surgically and the patient did not receive adjuvant or neoadjuvant therapy prior to presenting with metastases. Comparison of molecular testing results from the most recent primary and the liver metastases demonstrated ( a) a clonal relationship between the 2 cancers and ( 2) the presence of a KIF13B-NRG1 fusion and KRAS amplification unique to the metastases. When integrated, the molecular surgical pathology findings in this case illustrate the extent of "oncogenic drive" in preterminal lung cancer.

Entities:  

Keywords:  KRAS amplification; NRG1 fusion; lung cancer; molecular pathology

Mesh:

Substances:

Year:  2017        PMID: 28391773     DOI: 10.1177/1066896917693092

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  2 in total

1.  Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.

Authors:  Domenico Trombetta; Paolo Graziano; Aldo Scarpa; Angelo Sparaneo; Giulio Rossi; Antonio Rossi; Massimo Di Maio; Davide Antonello; Andrea Mafficini; Federico Pio Fabrizio; Maria Carmina Manzorra; Teresa Balsamo; Flavia Centra; Michele Simbolo; Angela Pantalone; Michela Notarangelo; Paola Parente; Maria Cecilia Lucia Dimitri; Antonio Bonfitto; Fabiola Fiordelisi; Clelia Tiziana Storlazzi; Alberto L'Abbate; Marco Taurchini; Evaristo Maiello; Vito Michele Fazio; Lucia Anna Muscarella
Journal:  Oncotarget       Date:  2018-01-03

2.  lncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1.

Authors:  Xianwei Li; Bo Chen; Decai Chi; Yingnan Zhang; Weiliang Jiang
Journal:  Onco Targets Ther       Date:  2019-01-07       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.